A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors

PURPOSE: Treatment of BRAF(V600E)-mutant melanomas with mitogen-activated protein kinase inhibitors (MAPKi) results in significant tumor regression, but acquired resistance is pervasive. To understand non-mutational mechanisms underlying the adaptation to MAPKi and to identify novel vulnerabilities...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Aloia, Andrea, Müllhaupt, Daniela, Chabbert, Christophe D., Eberhart, Tanja, Flückiger-Mangual, Stefanie, Vukolic, Ana, Eichhoff, Ossia, Irmisch, Anja, Alexander, Leila T., Scibona, Ernesto, Frederick, Dennie T., Miao, Benchun, Tian, Tian, Cheng, Chaoran, Kwong, Lawrence N., Wei, Zhi, Sullivan, Ryan J., Boland, Genevieve M., Herlyn, Meenhard, Flaherty, Keith T., Zamboni, Nicola, Dummer, Reinhard, Zhang, Gao, Levesque, Mitchell P., Krek, Wilhelm, Kovacs, Werner J.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906212/
https://ncbi.nlm.nih.gov/pubmed/31375515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0253
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars